Thyrotropin Alfa

Thyrotropin alfa (Thyrogen) is a real, FDA-approved recombinant TSH, used in thyroid cancer follow-up to stimulate any remaining thyroid tissue for testing or treatment — without requiring patients to stop their thyroid medication and become symptomatically hypothyroid first.

Avoiding deliberate hypothyroidism

Thyrotropin alfa is recombinant human thyroid-stimulating hormone (TSH), identical to the hormone your pituitary normally makes. In thyroid cancer patients who've had their thyroid surgically removed, doctors need to stimulate any remaining thyroid or cancer tissue — either to test thyroglobulin levels and take up radioactive iodine for a follow-up scan, or to prepare tissue for radioiodine remnant ablation treatment. Historically this required stopping thyroid hormone replacement for weeks, deliberately making the patient hypothyroid (fatigued, cognitively foggy, often clinically miserable) until TSH rose naturally. Thyrotropin alfa avoids that entirely — an injected dose raises TSH directly while the patient stays on their normal thyroid medication.

The approval and pivotal trial

The FDA approved thyrotropin alfa (as Thyrogen) in 1998 as a diagnostic aid for radioiodine scanning and thyroglobulin testing in post-thyroidectomy thyroid cancer follow-up, based on Ladenson et al. (N Engl J Med 1997, PMID 9302303), which compared thyrotropin-alfa-stimulated scanning against traditional thyroid-hormone-withdrawal scanning. A second, therapeutic indication — as an adjunct to radioiodine remnant ablation itself, not just diagnostic scanning — was approved in December 2007, based partly on Pacini et al. (J Clin Endocrinol Metab 2006, PMID 16384850), an international randomized trial of ablation success rates.

Safety

Thyrogen's label carries genuinely heavier warnings than most diagnostic peptide hormones on this site: rare reports of death in patients who had not had a full thyroidectomy or who had distant metastases, and rare stroke reports in young women within 72 hours of dosing. Tumor or thyroid-tissue swelling causing pain or compressive symptoms has also been reported, sometimes managed with pretreatment steroids. These are real, labeled concerns worth being precise about rather than treating this as a routine, risk-free injection.

Current status

Still marketed in the US by Sanofi (via its Genzyme unit). No grey-market or wellness-adjacent presence — a hospital/clinic-administered diagnostic and adjunct-treatment biologic.